2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 32

High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
Abstract Number: 68

HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Abstract Number: 125

How Do Health Literacy, Numeric Competencies and Patient Activation Impact Transition Readiness in Adolescents and Young Adults with Rheumatologic Diseases?
Abstract Number: 52

How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
Abstract Number: 41

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 23

Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Abstract Number: 70

Impact of Systemic Juvenile Idiopathic Arthritis/Still’s Disease on Adolescents as Evidenced Through Social Media Posting
Abstract Number: 100

Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
Abstract Number: 37

Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study
Abstract Number: 143

Influence of Age and Sex on Collagen-Induced Arthritis
Abstract Number: 132

Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study
Abstract Number: 105

Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
Abstract Number: 145

JAK Inhibition Rescues Novel PSMB8 Mutations
Abstract Number: 38

Knowledge Translation in Juvenile Idiopathic Arthritis Research in Canada: A Focus on Pediatric Rheumatologists and Allied Health Professionals
Abstract Number: 35

Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis: Potential for Targeted Immunotherapy

« Previous Page
1
…
4
5
6
7
8
…
11
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].